QQ客服 官方微博 反馈留言

	A phase III trial (ZJBI0009): CMABOO9 plus irinotecan versus irinotecan alone as second-line treatment after fluoropyrimidine and oxaliplatin failure in wild-type K-ras metastatic colorectal cancer patients.
	Shi, Yuankai; Li, Jin; Xu, Jianming; Cheng, Ying; Liu, Wei; Cheng, Yigui; Bai, Li; Zhang, Yiping; He, Xiaohui; Luo, Yi
	2017
卷号	35
ISSN号	0732-183X
DOI	10.1200/JCO.2017.35.15_suppl.3513
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6369336
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Shi, Yuankai,Li, Jin,Xu, Jianming,et al. A phase III trial (ZJBI0009): CMABOO9 plus irinotecan versus irinotecan alone as second-line treatment after fluoropyrimidine and oxaliplatin failure in wild-type K-ras metastatic colorectal cancer patients.[J],2017,35.
APA	Shi, Yuankai.,Li, Jin.,Xu, Jianming.,Cheng, Ying.,Liu, Wei.,...&Sun, Yan.(2017).A phase III trial (ZJBI0009): CMABOO9 plus irinotecan versus irinotecan alone as second-line treatment after fluoropyrimidine and oxaliplatin failure in wild-type K-ras metastatic colorectal cancer patients..,35.
MLA	Shi, Yuankai,et al."A phase III trial (ZJBI0009): CMABOO9 plus irinotecan versus irinotecan alone as second-line treatment after fluoropyrimidine and oxaliplatin failure in wild-type K-ras metastatic colorectal cancer patients.".35(2017).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。